Stock B1SX34 BOSTON SCIENTIFIC CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Boston Scientific Corporation Sao Paulo

Equities

B1SX34

BRB1SXBDR006

Advanced Medical Equipment & Technology

Market Closed - Sao Paulo
Other stock markets
 20:16:09 31/05/2024 BST 		5-day change 1st Jan Change
392.5 BRL +11.36% Intraday chart for Boston Scientific Corporation +1.14% +43.92%
05-31 Boston Scientific Insider Sold Shares Worth $4,791,447, According to a Recent SEC Filing MT
05-29 Transcript : Boston Scientific Corporation Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 08:00 AM

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 63,029 51,478 60,534 66,273 84,691 111,101 - -
Enterprise Value (EV) 1 72,820 58,887 67,674 74,280 92,928 117,525 114,725 111,030
P/E ratio 13.6 x -300 x 61.6 x 103 x 54 x 51.4 x 41.7 x 34.8 x
Yield - - - - - - - -
Capitalization / Revenue 5.87 x 5.19 x 5.09 x 5.23 x 5.95 x 6.95 x 6.32 x 5.76 x
EV / Revenue 6.78 x 5.94 x 5.69 x 5.86 x 6.53 x 7.35 x 6.52 x 5.75 x
EV / EBITDA 23.4 x 19.4 x 16.5 x 20.8 x 22.6 x 25.2 x 21.7 x 18.7 x
EV / FCF 53 x 52 x 51.4 x 79.2 x 51.9 x 52.2 x 39.4 x 28.7 x
FCF Yield 1.89% 1.92% 1.94% 1.26% 1.93% 1.92% 2.54% 3.48%
Price to Book 4.54 x 3.32 x 3.64 x 3.77 x 4.39 x 5.19 x 4.6 x 3.97 x
Nbr of stocks (in thousands) 1,393,824 1,431,921 1,424,992 1,432,311 1,464,983 1,470,180 - -
Reference price 2 45.22 35.95 42.48 46.27 57.81 75.57 75.57 75.57
Announcement Date 05/02/20 03/02/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 10,735 9,913 11,888 12,682 14,240 15,996 17,590 19,297
EBITDA 1 3,111 3,040 4,103 3,574 4,106 4,655 5,278 5,935
EBIT 1 2,800 1,917 3,010 3,241 3,738 4,283 4,812 5,405
Operating Margin 26.08% 19.34% 25.32% 25.56% 26.25% 26.77% 27.35% 28.01%
Earnings before Tax (EBT) 1 687 -138 1,076 1,141 1,985 2,628 3,271 3,868
Net income 1 4,700 -173 985 642 1,570 2,201 2,733 3,271
Net margin 43.78% -1.75% 8.29% 5.06% 11.03% 13.76% 15.54% 16.95%
EPS 2 3.330 -0.1200 0.6900 0.4500 1.070 1.471 1.811 2.175
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,251 2,915 3,865
FCF margin 12.81% 11.42% 11.07% 7.4% 12.58% 14.07% 16.57% 20.03%
FCF Conversion (EBITDA) 44.2% 37.24% 32.07% 26.25% 43.64% 48.36% 55.24% 65.13%
FCF Conversion (Net income) 29.26% - 133.6% 146.11% 114.14% 102.29% 106.66% 118.17%
Dividend per Share 2 - - - - - - - -
Announcement Date 05/02/20 03/02/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 3,127 3,026 3,244 3,170 3,242 3,389 3,599 3,527 3,725 3,856 4,021 3,958 4,178 4,233 4,425
EBITDA 1 1,109 1,055 898 892 928 947 1,052 1,011 1,095 1,316 1,142 1,133 1,221 1,321 1,324
EBIT 1 819 781 818 810 833 865 964 919 990 1,012 1,071 1,057 1,144 1,133 1,209
Operating Margin 26.19% 25.81% 25.22% 25.55% 25.69% 25.52% 26.79% 26.06% 26.58% 26.24% 26.64% 26.7% 27.38% 26.77% 27.32%
Earnings before Tax (EBT) 1 120 156 345 245 396 444 426 610 505 608 738.8 744 777.2 709 781
Net income 1 80 97 246 174 126 300 261 505 504 495 539.6 516.6 590.7 621.8 676.7
Net margin 2.56% 3.21% 7.58% 5.49% 3.89% 8.85% 7.25% 14.32% 13.53% 12.84% 13.42% 13.05% 14.14% 14.69% 15.29%
EPS 2 0.0600 0.0700 0.1700 0.1200 0.0900 0.2100 0.1800 0.3400 0.3400 0.3300 0.3603 0.3453 0.3988 0.4102 0.4462
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 02/02/22 27/04/22 27/07/22 26/10/22 01/02/23 26/04/23 27/07/23 26/10/23 31/01/24 24/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 9,791 7,409 7,140 8,007 8,237 6,423 3,623 -
Net Cash position 1 - - - - - - - 71.2
Leverage (Debt/EBITDA) 3.147 x 2.437 x 1.74 x 2.24 x 2.006 x 1.38 x 0.6865 x -
Free Cash Flow 1 1,375 1,132 1,316 938 1,792 2,251 2,915 3,865
ROE (net income / shareholders' equity) 19.8% 9.44% 14.1% 14.4% 16.3% 16.3% 17% 16.5%
ROA (Net income/ Total Assets) 8.67% 4.49% 7.42% 7.6% 8.87% 8.41% 9.35% 8.2%
Assets 1 54,241 -3,851 13,284 8,446 17,696 26,174 29,223 39,888
Book Value Per Share 2 9.950 10.80 11.70 12.30 13.20 14.60 16.40 19.00
Cash Flow per Share 2 1.300 1.060 1.300 1.060 1.710 2.590 2.970 3.440
Capex 1 461 376 554 588 711 692 735 776
Capex / Sales 4.29% 3.79% 4.66% 4.64% 4.99% 4.33% 4.18% 4.02%
Announcement Date 05/02/20 03/02/21 02/02/22 01/02/23 31/01/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Boston Scientific Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
75.57 USD
Average target price
82.06 USD
Spread / Average Target
+8.59%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+7.01% 215B
DANAHER CORPORATION Stock Danaher Corporation
+11.01% 187B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+19.20% 143B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.48% 64.68B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.95% 52.96B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.16% 49.84B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-6.20% 38.32B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+0.91% 35.86B
RESMED, INC. Stock ResMed, Inc.
+19.95% 30.75B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. BSX Stock
  4. B1SX34 Stock
  5. Financials Boston Scientific Corporation